Gilead Sciences (GILD) Free Cash Flow (2009 - 2026)
Gilead Sciences' (GILD) quarterly Free Cash Flow came in at $2.4 billion in Q1 2026, up 46.82% YoY from $1.7 billion in Q1 2025, and down 22.26% on a QoQ basis from $3.1 billion in Q4 2025.
Gilead Sciences (GILD) Free Cash Flow (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Free Cash Flow data on file, last reported at $2.4 billion in Q1 2026.
- Quarterly Free Cash Flow rose 46.82% year-over-year to $2.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.2 billion (up 3.92% YoY) and the FY2025 annual result came in at $9.5 billion, down 8.24% from the prior year.
- Free Cash Flow retreated to $2.4 billion in Q1 2026, from $3.1 billion in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $4.2 billion in Q3 2024 to a low of $720.0 million in Q2 2025.
- A 5-year average of $2.2 billion and a median of $2.1 billion in 2024 frame the typical range for Free Cash Flow.
- The widest YoY moves for Free Cash Flow: up 155.24% in 2024, down 45.66% in 2024.
- Tracing GILD's Free Cash Flow over 5 years: stood at $2.4 billion in 2022, then retreated by 18.11% to $2.0 billion in 2023, then surged by 44.73% to $2.8 billion in 2024, then rose by 10.4% to $3.1 billion in 2025, then slipped by 22.26% to $2.4 billion in 2026.
- The last three Free Cash Flow figures came in at $2.4 billion (Q1 2026), $3.1 billion (Q4 2025), and $4.0 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 7.30 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.11 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 4.48 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.56 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -1.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 3.49 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.43 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 302.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 440.07 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 2.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.43 Bn |
| Jun 30, 2026 | 3.43 Bn |
| Mar 31, 2026 | 2.43 Bn |
| Mar 31, 2026 | 2.43 Bn |
| Dec 31, 2025 | 3.12 Bn |
| Dec 31, 2025 | 3.12 Bn |
| Sep 30, 2025 | 3.96 Bn |
| Sep 30, 2025 | 3.96 Bn |
| Jun 30, 2025 | 720.00 Mn |
| Jun 30, 2025 | 720.00 Mn |
| Mar 31, 2025 | 1.65 Bn |
| Mar 31, 2025 | 1.65 Bn |
| Dec 31, 2024 | 2.83 Bn |
| Dec 31, 2024 | 2.83 Bn |
| Sep 30, 2024 | 4.17 Bn |
| Sep 30, 2024 | 4.17 Bn |
| Jun 30, 2024 | 1.20 Bn |
| Jun 30, 2024 | 1.20 Bn |
| Mar 31, 2024 | 2.11 Bn |
| Mar 31, 2024 | 2.11 Bn |